Solasia Pharma KK (4597) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Wakamoto Pharmaceutical Co., Ltd.

Solasia Pharma KK

Taiko Pharmaceutical Co., Ltd.

Healios KK

Nippon Chemiphar Co., Ltd.

Fuso Pharmaceutical Industries Ltd.

Noile-Immune Biotech, Inc.

BrightPath Biotherapeutics Co., Ltd.

SymBio Pharmaceuticals Ltd.

CanBas Co., Ltd.

Why is Solasia Pharma KK ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate -1.61% of over the last 5 years

With a growth in Net Sales of 43.83%, the company declared Outstanding results in Dec 25

OPERATING PROFIT(Q) Highest at JPY -138 MM
PRE-TAX PROFIT(Q) Highest at JPY -151 MM
NET PROFIT(Q) Highest at JPY -150 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -23.08%, its profits have fallen by -62.7%

Underperformed the market in the last 1 year

Even though the market (Japan Nikkei 225) has generated returns of 36.73% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -23.08% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Solasia Pharma KK should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Solasia Pharma KK for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Solasia Pharma KK

-23.08%

0.24

64.49%

Japan Nikkei 225

36.73%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-25.19%

EBIT Growth (5y)

-1.61%

EBIT to Interest (avg)

-229.10

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.23

Sales to Capital Employed (avg)

0.29

Tax Ratio

0.57%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.92

EV to EBIT

-2.95

EV to EBITDA

-3.13

EV to Capital Employed

-29.66

EV to Sales

17.40

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-224.80%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company

OPERATING PROFIT(Q)

Highest at JPY -138 MM

PRE-TAX PROFIT(Q)

Highest at JPY -151 MM

NET PROFIT(Q)

Highest at JPY -150 MM

NET SALES(Q)

Highest at JPY 338 MM

OPERATING PROFIT MARGIN(Q)

Highest at -40.83 %

EPS(Q)

Highest at JPY -0.53

-5What is not working for the Company

INTEREST(9M)

At JPY 20 MM has Grown at 566.67%

RAW MATERIAL COST(Y)

Grown by 34.84% (YoY

Here's what is working for Solasia Pharma KK

Net Sales

At JPY 338 MM has Grown at 43.83%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY -138 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (JPY MM)

Pre-Tax Profit

Highest at JPY -151 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY -150 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

Highest at JPY 338 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit Margin

Highest at -40.83 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

At JPY -151 MM has Grown at 85.86%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -150 MM has Grown at 85.98%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

EPS

Highest at JPY -0.53

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Here's what is not working for Solasia Pharma KK

Interest

At JPY 20 MM has Grown at 566.67%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Raw Material Cost

Grown by 34.84% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales